多発性硬化症における妊娠および乳児の転帰:グローバルMAPLE-MS医薬品安全性監視プログラムからの知見の概要
Kerstin Hellwig1, Hugh H Tilson2, Sandra Thiel3
1Neurological Clinic, University of Bochum, Bochum, Germany.
Abstract:
Information on pregnancy and infant outcomes after cladribine tablets exposure is limited, as its use is not recommended during pregnancy. This is a summary of the original published article 'Pregnancy and infant outcomes in multiple sclerosis: findings from the Global MAPLE-MS Pharmacovigilance Program'. The primary outcome is the prevalence of major congenital anomalies (MCAs) in babies. Secondary outcomes include other pregnancy outcomes (live birth, elective termination, spontaneous abortion, ectopic pregnancy, and stillbirth).
関連する概念動画
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Teratogenicity
Therapeutic Drug Monitoring: Affecting Factors
Mitral Valve Prolapse III: Nursing Management
Drug Dosing: Infants and Children
Bioavailability Study Design: Single Versus Multiple Dose Studies


